Abstract: It is an object of the present invention to provide a novel halogenated biotin-modified dimer capable of performing imaging diagnosis or treatment. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided: wherein L1 represents a trivalent linking group, L2 represents a divalent linking group, Hal represents a halogen, p represents an integer of 1 to 5, and q, r, s, and t each independently represent an integer of 1 to 8.

Abstract: It is an object of the present invention to provide a conjugate of a duocarmycin derivative and a biotin-modified dimer, which is useful for pretargeting methods. According to the present invention, a compound represented by the following formula (1) or formula (2) is provided: wherein R1 and R2 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; one of R3, R4, and R5 represents —O-L7-(Xaa)m-L6-N3, and the remaining two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; X represents a reactive group; L6 and L7 each independently represent a divalent linking group; Xaa represents an amino acid residue; m represents an integer of 2 to 10; and Me represents a methyl group.

Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).

Abstract: Objects of the present invention are to provide a novel phthalocyanine dye for use in photoimmunotherapy, and a method for producing the same, and to provide a conjugate of the above-described phthalocyanine dye and an antibody or a peptide. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided: wherein X represents a substituent having a hydrophilic group at the terminus thereof; L3, L4, L5, and L6 each independently represent a divalent linking group; Y represents a group capable of binding to an antibody or a peptide; R3 represents a substituent, such as an alkyl group containing 1 to 6 carbon atoms, an alkoxy group containing 1 to 6 carbon atoms, a halogen atom, —SR11, —SOR12, an aryl group containing 6 to 10 carbon atoms, —N(R13)(R14), or —NO2, wherein when a plurality of R3s are present, the plurality of R3s may be identical to or different from one another; and s represents an integer of 0 to 4.

Abstract: [Object] It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. [Means for Solution] A compound represented by the following formula (1) or a salt thereof: wherein X represents a substituent having a hydrophilic group, a cationic group or an amino group at the terminus thereof, or —OH, and other groups have the meanings as defined in the description.

Abstract: [Problem] The present invention addresses the problem of developing a catalyst compound which has blood-brain barrier penetration properties and enables the oxygenation of amyloids in a body upon being irradiated with light from the outside of the body and providing a prophylactic and therapeutic agent for amyloid-related diseases using the catalyst compound. [Solution] It is found that a compound having such a framework that an azobenzene-like structure and boron together form a complex is useful as a novel biocatalyst which can selectively oxygenate an amyloid and can prevent the aggregation of the amyloid upon being irradiated with light while significantly reducing the molecular weight of the amyloid. It is also found that the compound can exhibit an oxygenation activity upon the irradiation with light having a longer wavelength which has high tissue penetration properties and has excellent blood-brain barrier penetration properties.

Abstract: [Object] To provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. [Means for Solution] A fusion protein comprising a protein-recognizing substance and the amino acid sequence as set forth in SEQ ID NO: 19 that is fused with the protein-recognizing substance.

Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, and usage of them.

Abstract: It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order.

Abstract: Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably provided is a compound that has DOCK1-inhibiting activity and exerts an anticancer effect based on the activity.

Abstract: It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. The present invention provides a conjugate of a compound represented by the following formula (1) or a salt thereof and a phthalocyanine dye: wherein the meaning of each of symbols is as defined in the specification.

Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.

Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.

Abstract: An object of the present invention is to provide a halogenated biotin-modified dimer, which is capable of imaging diagnosis or treatment by labeling with a halogen, a biotin-modified dimer having a high affinity for a mutant streptavidin with a low affinity for natural biotin. The present invention provides a compound represented by the following formula (1) or a salt thereof: wherein the meaning of each symbol is the same as that described in the specification.

Abstract: An artificial catalyst system which can acylate chromosome proteins with high selectivity has successfully been established by using a combination of an acyl CoA activating catalyst having target acylation area binding ability and acyl CoA or a derivative thereof.

Abstract: Provided is a novel donor-acceptor type compound which emits light even in a solid state. The present invention provides an organic optical material comprising a complex formed from (1) a conjugated molecule having (a) at least one electron donating site, (b) at least one electron accepting site, and (c) at least one conjugated site in the same molecule and (2) a compound having a proton donating property or an electron pair accepting property, the complex having a non-covalent interaction at the electron accepting site, wherein the complex is solid at ordinary temperature; and the organic optical material has a property of emitting light having a maximum fluorescence wavelength which causes a Stokes shift having a value corresponding to 5% or more of the value of a maximum absorption wavelength from the maximum absorption wavelength toward the long wavelength side.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.

Abstract: An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.

Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.